This month
The tanning shot just got $101,412 in fines — and the discourse returned with it
In May 2026, Australia's Therapeutic Goods Administration issued 27 infringement notices totalling $101,412 to a NSW-based individual for the alleged unlawful supply of Melanotan-II to Australian consumers. The enforcement action followed regulatory changes earlier this year that reclassified Melanotan-II to Schedule 9 in Australia — the same scheduling tier as MDMA and heroin — based on adverse event reports that included documented melanoma cases among long-term users. [The TGA media release](https://www.tga.gov.au/news/media-releases/individual-issued-27-infringement-notices-allegedly-supplying-melanotan-ii) is the most recent in a pattern of escalating enforcement: the agency has been explicit that Melanotan-II is not an approved therapeutic good in Australia, and that anyone supplying it for human use is doing so illegally. The cultural label arrived well before the crackdown. Melanotan-II became the Barbie drug on TikTok and in tabloids: a self-injected tanning compound that users claimed produced a year-round tan with minimal sun exposure. What the discourse rarely included was the mechanism. The peptide family at the center of this month's enforcement action is the same family that produced an FDA-approved medicine in 2019. Those two outcomes don't cancel each other out. They explain each other.
The actual biology
What melanocortin receptors do — and why there are five of them
Melanocortin peptides derive from proopiomelanocortin, a pituitary precursor protein cleaved into multiple signaling molecules including alpha-MSH, beta-MSH, and ACTH. All of them bind to five distinct receptor subtypes — MC1R through MC5R — each with a different tissue distribution and functional profile. MC1R sits primarily in melanocytes and is the target responsible for tanning: activation drives melanin production and shifts pigmentation toward eumelanin, the darker pigment variant. This is the receptor that made Melanotan-II notorious. It was designed as a non-selective melanocortin agonist that activates multiple subtypes simultaneously, including both MC1R and MC4R. MC4R is where the pharmacology gets more consequential. It is expressed in the hypothalamus and brainstem structures involved in appetite regulation, energy balance, and autonomic output — including the pathways that govern sexual arousal. When Melanotan-II was first studied as a tanning compound in early clinical trials, the unexpected finding was spontaneous erection. That observation reframed the research. A compound designed to change skin color was pointing toward a different receptor, a different indication, and eventually a different regulatory process. [The PubMed literature on melanocortin receptor pharmacology](https://pubmed.ncbi.nlm.nih.gov/?term=melanocortin+receptor+bremelanotide) documents where that research trajectory traveled over the following two decades.
What the internet says
PT-141 is the sex peptide — and the label says something more specific than that
Bremelanotide traveled through the research-peptide ecosystem under a different name: PT-141. In that form, it became one of the more widely discussed gray-market compounds in the libido and sexual-performance space — marketed and discussed as a demand-based option for both men and women, with claims ranging from modest (libido improvement) to extravagant (enhanced arousal, mood effects, performance outcomes across a broad population). The framing consistently outran the evidence. The approved version, Vyleesi, is a subcutaneous auto-injector for one specific population: premenopausal women with a clinical diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD). That limitation exists because it is what the clinical trials tested, what the data supported, and what the FDA reviewed. For men, the available evidence runs back to early Phase 1 and Phase 2 intranasal PT-141 trials that produced encouraging preliminary data on arousal response — roughly 34 percent of participants achieved erections sufficient for intercourse versus around 9 percent for placebo in one early study. That is interesting early-phase data. It is not an approved indication, and it did not produce a New Drug Application submission. The PT-141 gray market claims all of it simultaneously. The regulatory record distinguishes one specific approval from everything else.
What the data actually shows
A Phase 3 program that hit its co-primary endpoints — in one defined population
The pivotal evidence for bremelanotide comes from the Phase 3 RECONNECT program — two parallel randomized, double-blind, placebo-controlled trials that enrolled approximately 1,200 premenopausal women with a formal clinical diagnosis of acquired, generalized HSDD. Both trials met their co-primary endpoints at 24 weeks: statistically significant improvement in sexual desire scores and a reduction in distress associated with low sexual desire. The FDA granted approval for Vyleesi in June 2019 based on these results. [The DailyMed label for bremelanotide](https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=bremelanotide) is the document that defines what that approval covers — the specific indication, the studied population, the known adverse effect profile, and the contraindications. Nausea is the most commonly reported adverse effect, occurring in roughly 40 percent of trial participants. Facial flushing and headache were also reported at rates above placebo. [ClinicalTrials.gov for bremelanotide](https://clinicaltrials.gov/search?term=bremelanotide) shows the full registered trial history, including the RECONNECT studies and the earlier Phase 2 work in men that generated initial interest. The trial record makes visible the gap that the gray-market narrative doesn't: what Phase 2 findings look like versus what a completed NDA submission looks like, and why one produces an approved label and the other remains investigational.
Approved — PeptideFactCheck stance
One specific approval in a peptide family with three distinct regulatory paths
Bremelanotide carries the Approved evidence tier on PeptideFactCheck, and that means one precise thing: regulatory certainty exists for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women, using the approved Vyleesi formulation. That is what the clinical program tested, what the FDA reviewed through the NDA process, and what the label specifies. It does not extend to other populations, other conditions, off-label use cases, or the broader PT-141 product ecosystem. The melanocortin family actually contains three distinct FDA-approved pathways. Afamelanotide, targeting MC1R, earned approval for a specific photoprotection condition in erythropoietic protoporphyria. Setmelanotide, also an MC4R agonist, earned approval for rare genetic obesity syndromes involving specific gene variants. Bremelanotide earned approval for HSDD. Each approval required its own clinical program, its own indication, and its own evidence. None of them validates melanocortin receptor activation as a general wellness, tanning, or performance pathway — and none of them is what gets sold online under research-peptide labels. The May 2026 TGA enforcement action represents the regulatory system reaching its own conclusion about what happens when that distinction collapses. Supplying an unapproved melanocortin agonist and a legitimate approved peptide medicine are not the same category. The clinical record that separates them has been public since 2019.
Editorial boundary
What this page will not do
It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.